Esophageal Cancer Presentation, Treatment, and Outcomes Vary With Hospital Safety-Net Burden

Ann Thorac Surg. 2019 May;107(5):1472-1479. doi: 10.1016/j.athoracsur.2018.11.065. Epub 2018 Dec 31.

Abstract

Background: Social determinants of health affect diagnosis and delivery of care to patients with esophageal cancer. This study hypothesized that hospital safety-net burden affects presentation, treatment, and outcomes in patients with esophageal cancer.

Methods: The National Cancer Database was queried for patients with esophageal cancer (2004 to 2013). Treating facilities were categorized according to their relative burden of uninsured or Medicaid-insured patients. Hospitals with low (LBH), medium (MBH), and high (HBH) safety-net burden were compared with respect to patient demographics, disease and treatment characteristics, and survival using χ2 analysis, Kaplan-Meier survival analysis, and multivariable modeling.

Results: There were 56,115 patients from 1,215 facilities. HBH treated a greater proportion of racial and ethnic minorities and patients with lower socioeconomic status. Patients at HBH presented at later stages and received primary surgical therapy less often than at MBH and LBH. Survival for patients with esophageal adenocarcinoma did not differ significantly between HBH and LBH after adjusting for age, sex, race, ethnicity, income, comorbidity, stage, histologic type, tumor location, facility type, insurance status, and treatment modality (hazard ratio, 1.06; 95% confidence interval, 0.99 to 1.14; p = 0.093). HBH were associated with a higher mortality risk than LBH for patients with squamous cell carcinoma (hazard ratio, 1.11; 95% confidence interval, 1.02 to 1.20; p = 0.014).

Conclusions: There is a mortality risk for patients with squamous cell carcinoma, but not for adenocarcinoma at HBH compared with LBH. Further analysis of unadjusted variables such as performance status, completion of therapy, and continuity of care, and others should be undertaken among safety-net hospitals with the goal of creating appropriate clinical pathways for care of esophageal cancer in vulnerable populations.

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / epidemiology*
  • Adenocarcinoma / therapy
  • Aged
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / epidemiology*
  • Carcinoma, Squamous Cell / therapy
  • Combined Modality Therapy
  • Databases, Factual
  • Esophageal Neoplasms / diagnosis
  • Esophageal Neoplasms / epidemiology*
  • Esophageal Neoplasms / therapy
  • Esophagectomy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Safety-net Providers*
  • Socioeconomic Factors
  • Survival Rate
  • Treatment Outcome

Supplementary concepts

  • Adenocarcinoma Of Esophagus